<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02218736</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00052485</org_study_id>
    <secondary_id>HHSN271201200006I</secondary_id>
    <nct_id>NCT02218736</nct_id>
  </id_info>
  <brief_title>Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a</brief_title>
  <acronym>FASTMAS_Kor2</acronym>
  <official_title>A Phase 2a Study to Evaluate the Kappa Opioid Receptor As a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluation of Whether CERC-501 Engages Key Neural Circuitry Related to the Hedonic Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The available treatment for patients with mood and anxiety disorders have significant
      limitations (Rush, 2007; Denys and de Geus, 2005). There is a need to develop new treatments
      for people with these disorders. Many research studies carried out in animals and a few
      preliminary studies carried out in humans suggest that medications which block kappa opioid
      receptors (KOR) have potential for being effective new treatments for patients with mood and
      anxiety spectrum disorders. These medications have shown particular promise for improving one
      important type of difficulty experienced by many patients who suffer from mood and anxiety
      spectrum disorders referred to as anhedonia, which is an impairment in reward-related
      function. In this study we will test the hypothesis that KOR antagonism is a promising means
      of improving anhedonia in patients with mood and anxiety spectrum disorders. We will do so by
      evaluating whether we can establish Proof of Concept (POC) that a relatively selective KOR
      antagonist, CERC-501 (formerly known as LY2456302), engages neural circuits involved in
      mediating reward-related function in patients with mood and anxiety spectrum disorders with
      anhedonia. We are attempting to establish POC in this study in order to determine whether
      there is a sufficient basis for pursuing future work evaluating whether KOR antagonism has
      therapeutic effects on clinical and behavioral measures of reward-related functioning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FAST-MAS addresses an important problem and critical barrier to progress in Mood and Anxiety
      Spectrum Disorders and if the aims of the project are achieved, FAST-MAS could shift
      scientific knowledge, technical capacity, and clinical practice in a positive direction.

      The Mood and Anxiety Spectrum disorders are both extremely common and associated with
      significant morbidity and mortality and, as such, represent an important public health
      problem in the United States.

      The mood disorders include the following diagnostic entities: major depressive disorder
      (MDD), bipolar disorder (including subtypes of mania, mixed state, and depressed, as well as
      types I and II), and dysthymic disorder. Available epidemiologic data suggest that the
      prevalence of these mood disorders is extremely high among adults in the United States,
      approaching 10%. Among the mood disorders, MDD has high lifetime prevalence, with recent
      estimates up to 16%. According to the World Health Organization (WHO), MDD is currently the
      leading cause of disability with the greatest burden of illness in developed countries and
      the third most common cause of disability worldwide. MDD is life shortening due to both
      suicide and its association with increased mortality from other medical conditions. It is
      also a highly recurrent condition with between 50% and 75% of persons diagnosed with MDD
      experiencing more than one episode. Bipolar Disorder is also a highly recurrent condition.
      The lifetime prevalence of bipolar disorder has been estimated to be approximately 3.4% in
      the World Health Survey Initiative. Approximately 60% of affected individuals experience
      severe or very severe role impairment based on the Sheehan Disability Scale and, like MDD,
      bipolar disorder is associated with significant suicide risk.

      The anxiety disorders are also very common and associated with significant adverse impact on
      affected individuals and society. These disorders include the following diagnostic entities:
      generalized anxiety disorder (GAD), panic disorder, obsessive-compulsive disorder, social
      phobia, specific phobias, and post-traumatic stress disorder (PTSD). As a group, these
      conditions affect approximately 18% of adults in a given year and they are associated with
      significant co-morbidities and adverse consequences. Of the anxiety disorders, GAD appears to
      be associated with the greatest per patient cost and disability with a degree of disability
      comparable to that of MDD and comparable to chronic medical conditions such as arthritis,
      diabetes, and peptic ulcer disease. It affects approximately 6.8 million adults in the U.S.
      and is a highly chronic condition. Panic disorder affects about 6 million American adults and
      is twice as common in women as men. Panic disorder is also highly disabling and often chronic
      and even mild forms of this disorder are linked to significantly increased impairment in
      function and quality of life as well as a number of comorbidities. Approximately 2.2 million
      adults in the U.S. are affected by obsessive-compulsive disorder and this disorder is often
      accompanied by psychiatric comorbidities. Roughly half of individuals with this condition
      have a chronic unremitting course which is associated with significant disability and
      morbidity. Social phobia, also known as social anxiety disorder, is seen in roughly 15
      million adults in the U.S. and is often associated with MDD or other anxiety disorders. It is
      generally a chronic condition that leads to a great degree of disability due to substantial
      impairment in social, educational, and occupational function. Approximately 8 million adults
      in the U.S. experience PTSD and approximately 12% of the population have PTSD at some point
      in their lives and affected individuals frequently experience associated MDD, other anxiety
      disorders and substance use problems. The level of disability associated with this condition
      tends to be quite high and includes impairment in social and occupational function and
      quality of life. There are also substantial financial and social costs associated with PTSD
      due to increased hospitalization rates, suicidality, and substance use problem.

      Mood disorders and anxiety disorders are highly prevalent conditions, many of which are
      chronic, nearly all of which are associated with substantial comorbidities, disability and
      impairment and some are associated with an increased risk for mortality. Despite the
      availability of many pharmacologic, psychotherapeutic, brain stimulation, and combination
      treatment options available to clinicians, many patients with Mood and Anxiety Spectrum
      Disorders respond poorly to treatment. In light of the impairments, costs, and risks of these
      disorders, the limitations of the available treatments represents an enormous burden to
      public health and speak strongly to the need for new treatments for these conditions as well
      as novel methodologies of treatment development that are not only faster than existing
      methodologies but which also promote new ways of thinking about these disorders and their
      treatment and capitalize on recent and ongoing developments in basic science.

      This study will be a six-site randomized, double-blind, PBO (placebo) -controlled,
      parallel-group mono-therapy study to assess the effects of CERC-501 (formerly known as
      LY2456302) compared to PBO in adults age 21-65 years with mood and anxiety spectrum
      disorders. We will recruit a total of 90 subjects, of which 45 will be randomized to CERC-501
      and 45 to placebo for 8 weeks of treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">December 1, 2017</completion_date>
  <primary_completion_date type="Actual">November 1, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional MRI evaluation of task-related ventral striatal activation occurring with reward and anticipation during the Monetary Incentive Delay Task</measure>
    <time_frame>Week 8</time_frame>
    <description>Establish POC for KOR antagonism by evaluating the impact of CERC-501 relative to Placebo on reward-related neural circuitry in terms of ventral striatal activation during anticipation of reward during the Monetary Incentive Delay Task. Evaluation by fMRI after 8 weeks of daily drug dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Anhedonia measured by the Snaith-Hamilton Pleasure Scale (SHAPS; total score)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To determine if CERC-501 is superior to placebo in improving a clinical self-report measure of anhedonia using the Snaith Hamilton Pleasure Scale (SHAPS). The SHAPS will be collected at all study visits including week 12 follow-up. It will be used to screen subjects for having anhedonia as part of inclusion/exclusion assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral measure of anhedonia using the Probabilistic Reward Task</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the impact of CERC-501 relative to placebo on a behavioral measure of anhedonia using the Probabilistic Reward Task (PRT). The PRT will be carried out at baseline and after 8 weeks of double-blind treatment to assess the effects on a behavioral outcome measure that assessed reward-related function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)</condition>
  <arm_group>
    <arm_group_label>CERC-501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dosing of 10 mg CERC-501 (formerly known as LY2456302) administered daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral daily administration of 10 mg placebo for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CERC-501</intervention_name>
    <description>Oral dosing of 10 mg CERC-501 daily for 8 weeks</description>
    <arm_group_label>CERC-501</arm_group_label>
    <other_name>Kappa Opioid Receptor Antagonist; LY2456302</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral dosing of 10 mg placebo daily for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 21 and 65 years of age

          -  Must meet DSM-IV TR (Diagnostic and Statistical Manual of Mental Disorders, 4th
             edition, text revision) diagnostic criteria for: Major Depressive Disorder, Bipolar I
             or II Depressed, Generalized Anxiety Disorder, Social Phobia, Panic Disorder, or Post
             Traumatic Stress Disorder

          -  Snaith-Hamilton Pleasure Scale (SHAPS) score â‰¥ 20

          -  Reliable and willing to be available for the duration of the study

          -  Willing and able to give written informed consent to participate

          -  Able to understand and comply with instructions

          -  If female of childbearing potential, must agree to use dual methods of contraception
             and be willing and able to continue contraception for 6 weeks after the last dose of
             study drug. Females using oral contraception must have started using it at least 2
             months prior to the Baseline Visit

          -  If male of childbearing potential, must have undergone surgical sterilization (such as
             a vasectomy) or agree to use a condom used with a spermicide during participation in
             the study and for 1 month afterward

        Exclusion Criteria:

          -  Expected to require hospitalization during the course of the study

          -  Current/history of a psychotic disorder, current manic or mixed episode, autism
             spectrum disorders, mental retardation

          -  Met DSMIV-TR (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text
             revision) criteria for substance abuse within the last 3 months or substance
             dependence within the last 6 months, excluding caffeine and/or nicotine

          -  History of unstable or untreated serious medical condition based on physician
             evaluation, medical history, and screening laboratory testing

          -  Active suicidal intent or plan, or history of attempt within the past 3 months based
             on physician evaluation and Columbia Suicide Severity Rating Scale (C-SSRS)

          -  Use of any antidepressant, antipsychotic, anxiolytic, anticonvulsant, mood
             stabilizing, muscle relaxant, centrally acting antihistaminergic, stimulant or
             insomnia medications (See Appendix 2) within 5 half-lives of baseline or at any time
             during after baseline

          -  Use of any medication that is primarily metabolized by Cytochrome P450 2C8 within 14
             days of baseline or at any time during the study. This includes: Cerivastatin,
             Paclitaxel, Repaglinide, Sorafenib, Rosiglitazone, Trimethoprim, Amodiaquine,
             Morphine, Amiodarone, Cabazitaxel, Carbamazepine, Chloroquine, Ibuprofen, Trepostinil,
             Torsemide.

          -  Any contraindications to the magnetic resonance imaging procedures

          -  Positive urine drug screen at any time during the study

          -  Use of any investigational medication within 3 months prior to the start of this study
             or scheduled to receive an investigational drug other than the study drug during the
             course of this study

          -  Known hypersensitivity to CERC-501 (formerly known as LY2456302)

          -  History of severe allergies or multiple adverse drug reactions

          -  History of gastric disease (including peptic ulcer disease, gastritis, upper GI
             bleeding, or any GI precancerous condition), current clinically evident
             gastrointestinal complaints, or positive urea breath test

          -  Current use of a proton pump inhibitor or histamine 2 blocker, or a history of chronic
             NSAID (nonsteroidal anti-inflammatory drug) use.

          -  History of use of Salvia divinorum or use of Salvia divinorum at any time during the
             study.

          -  Any other condition that in the opinion of the investigator would preclude
             participation in the study

          -  Any smoking of cigarettes or use of other nicotine containing products within the last
             month or at any time during the study

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard D Weiner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrew Goddard, MD</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-l7176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CaseWestern Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>70030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, Forster BM, Wong CJ, Li X, Crile RS, Shaw DB, Sahr AE, Adams BL, Quimby SJ, Diaz N, Jimenez A, Pedregal C, Mitch CH, Knopp KL, Anderson WH, Cramer JW, McKinzie DL. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014 Feb;77:131-44. doi: 10.1016/j.neuropharm.2013.09.021. Epub 2013 Sep 23.</citation>
    <PMID>24071566</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2014</study_first_submitted>
  <study_first_submitted_qc>August 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2014</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anhedonia</keyword>
  <keyword>Mood and Anxiety Spectrum Disorders</keyword>
  <keyword>CERC-501 (investigational product)</keyword>
  <keyword>Kappa Opioid Receptor (KOR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Narcotic Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

